Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The amyloid cascade hypothesis has always been a research focus in the therapeutic field of Alzheimer's disease (AD) since it was put forward. Numerous researchers attempted to find drugs for AD treatment based on this hypothesis. To promote the research of anti-AD drugs development, the current hypothesis and pathogenesis were reviewed with expounding of β-amyloid generation from its precursor protein and related transformations. Meanwhile, the present drug development strategies aimed at each stage in this hypothesis were also summarized. Several strategies especially immunotherapy showed the optimistic results in clinical trials, but only a small percentage of them eventually succeeded. In this review, we also tried to point out some common problems of drug development in preclinical and clinical studies which might be settled through multidisciplinary cooperation as well as the understanding that reinforces the amyloid cascade hypothesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Conserved cell types with divergent features in human versus mouse cortex
Hodge, R. D., Bakken, T. E., Miller, J. A., Smith, K. A., Barkan, E. R., Graybuck, L. T., Close, J. L., Long, B., Johansen, N., Penn, O., et al. (2019) · Nature · doi:10.1038/s41586-019-1506-7 · Cited by 1,775 · cited 1×
“The human cerebral cortex, compared with mice, possesses conservative basic structure and cortical development while the area and number of neurons increased 1,000fold [95-97].”
BackgroundAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“However, the clinical trials of drugs targeting Aβ are challenging with a 99% failure rate [13-15].”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“A673T, a coding mutation of the APP gene, could inhibit the β-cleavage of APP and consequently reduce the level of Aβ formation by approximately 40% [18].”
BackgroundUniquely Hominid Features of Adult Human Astrocytes
Oberheim, N. A., Takano, T., Han, X., He, W., Lin, J. H. C., Wang, F., Xu, Q., Wyatt, J. D., Pilcher, W., Ojemann, J. G., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4707-08.2009 · Cited by 1,488 · cited 1×
“Besides, some specialized features were confirmed in the human brain, such as the presence of interlaminar astrocytes and rosehip neurons and the expansion of superficial cortical layers [98-100].”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“It was first reported that the level of Aβ was decreased by administrated immunotherapy in 2002, but the cognitive improvement didn't appear with it [76].”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Alzheimer's disease drug development pipeline: 2019
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.008 · Cited by 762
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675 · cited 1×
“In addition to discovering new molecules with occupancy-based pharmacological activity, is also promising to induce the degradation of important proteins by difunctional molecules such as proteolysis-targeting chimera (PROTAC) [109] and autophagy-targeting chimera (AUTAC) [110], which is known as targeted protein degr…”
BackgroundKuhn, P., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., Kremmer, E., Roßner, S., & Lichtenthaler, S. F. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.167 · Cited by 621 · cited 2×
“In addition, there is a non-amyloidogenic pathway that is parallel and competitive with the amyloidogenic pathway [30-32].”
Background: Cellular scaling rules for rodent brains.
Herculano-Houzel, S., Mota, B., & Lent, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604911103 · Cited by 579 · cited 1×
“The human cerebral cortex, compared with mice, possesses conservative basic structure and cortical development while the area and number of neurons increased 1,000fold [95-97].”
BackgroundAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 1×
“However, the clinical trials of drugs targeting Aβ are challenging with a 99% failure rate [13-15].”
BackgroundRandomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · cited 1×
“However, it was failed due to the invalid effect, while the cognition and daily function were even worse in the verubecestat administered group than that of the placebo to some degree [51].”
BackgroundAlzheimer’s disease drug development pipeline: 2021
Cummings, J., Lee, G., Zhong, K., Fonseca, J., & Taghva, K. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12179 · Cited by 539 · cited 5×
“At present, Aβ is the most common target in the clinical trial for the treatment of AD [12].”
BackgroundMethodInfluentialThe Evolution of the Brain, the Human Nature of Cortical Circuits, and Intellectual Creativity
DeFelipe, J. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00029 · Cited by 527 · cited 1×
“The human cerebral cortex, compared with mice, possesses conservative basic structure and cortical development while the area and number of neurons increased 1,000fold [95-97].”
BackgroundAlafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467 · cited 1×
“β-amyloid (Aβ) deposition, which was first discovered in cerebrovascular patients in the 1980s, is regarded as the leading cause of AD [10].”
BackgroundA two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II
Matthews, F. E., Stephan, B. C. M., Robinson, L., Jagger, C., Barnes, L. E., Arthur, A., Brayne, C., Cognitive Function and Ageing Studies (CFAS) Collaboration, Comas-Herrera, A., Wittenberg, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11398 · Cited by 426 · cited 1×
“It is estimated that the number of people with AD will reach around 100 million by 2050 around the world [2].”
Backgroundβ-Amyloid burden in healthy aging: Regional distribution and cognitive consequences
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., Mathews, D., & Park, D. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318245d295 · Cited by 419
The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
Jorissen, E., Prox, J., Bernreuther, C., Weber, S., Schwanbeck, R., Serneels, L., Snellinx, A., Craessaerts, K., Thathiah, A., Tesseur, I., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5221-09.2010 · Cited by 363 · cited 1×
“In addition, there is a non-amyloidogenic pathway that is parallel and competitive with the amyloidogenic pathway [30-32].”
BackgroundTranscriptomic and morphophysiological evidence for a specialized human cortical GABAergic cell type
Boldog, E., Bakken, T. E., Hodge, R. D., Novotny, M., Aevermann, B. D., Baka, J., Bordé, S., Close, J. L., Diez-Fuertes, F., Ding, S.-L., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0205-2 · Cited by 291 · cited 1×
“Besides, some specialized features were confirmed in the human brain, such as the presence of interlaminar astrocytes and rosehip neurons and the expansion of superficial cortical layers [98-100].”
BackgroundSoluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generation
Obregon, D., Hou, H., Deng, J., Giunta, B., Tian, J., Darlington, D., Shahaduzzaman, M., Zhu, Y., Mori, T., Mattson, M. P., et al. (2012) · Nature Communications · doi:10.1038/ncomms1781 · Cited by 192
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease
Zhang, Z., Obianyo, O., Dall, E., Du, Y., Fu, H., Liu, X., Kang, S. S., Song, M., Yu, S.-P., Cabrele, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14740 · Cited by 146 · cited 1×
“It showed good permeation of the blood-brain barrier in mice models and negligible toxicities through long-term administration [58, 59], while its clinical effect remained to be studied.”
BackgroundRoscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139 · cited 1×
“It was reported that the roscovitine derivative (R)-DRF053 (2) possesses potent and dose-dependent CK1 inhibition with an IC50 value of 14 nM and low cytotoxicity in the SH-SY5Y cell model [48, 49].”
BackgroundAntiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126 · cited 2×
“Encouragingly, some attempts in clinics are sanguine [90].”
BackgroundKojro, E., Postina, R., Buro, C., Meiringer, C., Gehrig‐Burger, K., & Fahrenholz, F. (2006) · The FASEB Journal · doi:10.1096/fj.05-4812fje · Cited by 118
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice
Chen, Y., Zhao, S., Fan, Z., Li, Z., Zhu, Y., Shen, T., Li, K., Yan, Y., Tian, J., Liu, Z., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00761-9 · Cited by 111
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Ray, B., Maloney, B., Sambamurti, K., Karnati, H. K., Nelson, P. T., Greig, N. H., & Lahiri, D. K. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0709-x · Cited by 91
F. Lichtenthaler, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799361655 · Cited by 76
The Problem of Aducanumab for the Treatment of Alzheimer Disease
Alexander, G. C., & Karlawish, J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2603 · Cited by 47 · cited 4×
“Food and Drug Administration (FDA) on June 7, 2021 [16], which encouraged the drug's development aiming at the Aβ pathway.”
BackgroundInfluentialChen, G., Kang, S. S., Wang, Z., Ahn, E. H., Xia, Y., Liu, X., Sandoval, I. M., Manfredsson, F. P., Zhang, Z., & Ye, K. (2021) · Science Advances · doi:10.1126/sciadv.abe4499 · Cited by 44
APP intracellular domain–WAVE1 pathway reduces amyloid-β production
Ceglia, I., Reitz, C., Gresack, J., Ahn, J.-H., Bustos, V., Bleck, M., Zhang, X., Martin, G., Simon, S. M., Nairn, A. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3924 · Cited by 41 · cited 1×
“As a result, the production of Aβ was limited [41].”
BackgroundAlzheimer’s disease research: The future of BACE inhibitors
Burki, T. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31425-9 · Cited by 40 · cited 2×
“Yet most of the evidence so far suggests the amyloid cascade hypothesis still makes sense, especially in the condition of a presymptomatic phase of AD or in the very mild cognitive impairment stage [53].”
BackgroundGDE2-RECK controls ADAM10 α-secretase–mediated cleavage of amyloid precursor protein
Nakamura, M., Li, Y., Choi, B.-R., Matas-Rico, E., Troncoso, J., Takahashi, C., & Sockanathan, S. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6178 · Cited by 38 · cited 1×
“sAPPα is a neuroprotective fragment [34], competitively interacting with β-secretase and preventing the β-secretase mediated APP degradation in the amyloidogenic pathway [35].”
BackgroundTakeda, K., Uda, A., Mitsubori, M., Nagashima, S., Iwasaki, H., Ito, N., Shiiba, I., Ishido, S., Matsuoka, M., Inatome, R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01720-2 · Cited by 32
Cho, W.-H., Park, J.-C., Kim, D.-H., Kim, M.-S., Lee, S.-Y., Park, H., Kang, J.-H., Yeon, S.-W., & Han, J.-S. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.036 · Cited by 13 · cited 1×
“In one investigation conducted on 5Xfamilial AD (FAD) mice, ID1201 treatment reduced insoluble Aβ42 and increased sAPPα level, indicating that it could be used to treat AD [66].”
BackgroundWu, D., Hu, Y., Song, M., & Li, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.634948 · Cited by 7 · cited 1×
“It was reported that some environmental pollutants such as dichlorodiphenyltrichloroethane (DDT) could inhibit the expression of ABCA1 and slow down the clearance of Aβ by decreasing the level of mRNA and protein of the liver X receptor α (LXRα), an ABCA1 autoregulatory transcription factor [38].”
Background
Cited by
Hein, Z. M., Karikalan, B., Gopalakrishna, P. K., Dhevi, K., Alkatiri, A., Hussan, F., Mohd Moklas, M. A., Jagadeesan, S., Che Ramli, M. D., Che Mohd Nassir, C. M. N., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05602-0 · Cited by 43
Network Dynamics‐based Subtyping of Alzheimer's Disease With Microglial Genetic Risk Factors
Choi, J. H., Lee, J., Kang, U., Chang, H., & Cho, K.-H. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01583-9 · Cited by 7
The transcriptional and cellular landscape of cognitive resilience to Alzheimer’s disease
Khera, N., Raju, R. M., & Lipton, S. A. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1665802 · Cited by 3
Metadata
- Authors
- Wu, T., Lin, D., Cheng, Y., Jiang, S., Riaz, M. W., Fu, N., Mou, C., Ye, M., & Zheng, Y.
- Venue
- Aging and disease
- Publisher
- Aging and Disease
- Published
- 2022
- Volume
- 13
- Issue
- 6
- Pages
- 1745
- ISSN
- 2152-5250 (ISSN-L)
- OpenAlex
- W4310776371
- Cited by
- 73
- References
- 40
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.